Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.71 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145978 | 0.86 | BACE1 (0.64) | BACE1TLR8BRD4MEN1KMT2A | |
| SCHEMBL4508981 | 0.85 | BACE1 (0.67) | BACE1 | |
| SCHEMBL4136983 | 0.83 | BACE1 (1.00) | BACE1 | |
| SCHEMBL4134810 | 0.82 | BACE1 (0.85) | BACE1 | |
| SCHEMBL27702335 | 0.81 | BACE1 (0.49) | BACE1TLR8ADORA1 | |
| SCHEMBL4512841 | 0.80 | BACE1 (0.72) | BACE1TLR8BRD4 | |
| SCHEMBL4134504 | 0.79 | BACE1 (0.81) | BACE1 | |
| SCHEMBL4493177 | 0.78 | BACE1 (0.63) | BACE1ADORA1 | |
| SCHEMBL4640096 | 0.78 | BACE1 (0.57) | BACE1BRD4MEN1KMT2A | |
| SCHEMBL4639694 | 0.78 | BACE1 (0.57) | BACE1BRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | BACE1 3/4885TLR8 4136/4885BRD4 3927/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | BACE1 4/4885TLR8 4240/4885BRD4 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.